Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼Ò¾Æ ¾ß´¢Áõ ȯÀÚ¿¡ ´ëÇÑ º¹Çվ๰¿ä¹ýÀÇ È¿°ú Effects of Combined Drug Therapy in the Nocturnal Enuretic Patients

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 1È£ p.70 ~ 76
Á¤Á¤À±, ±è±¤¸í,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤Á¤À± (  ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç

±è±¤¸í (  ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

°á·Ð
ÀúÀÚµéÀº 1996³â 7¿ùºÎÅÍ 1997³â 2¿ù »çÀÌ¿¡ ¾ß´¢ÁõÀ» ÁÖ¼Ò·Î ¼­¿ï´ëÇк´¿ø ¼Ò¾Æº´¿ø ºñ
´¢±â°ú ¿Ü·¡¸¦ ¹æ¹®ÇÑ È¯ÀÚÁß ¼±º°°Ë»ç¿¡¼­ ±âÁúÀû ÀÌ»óÀÌ ¾ø°í ÀÏÁÖÀÏ¿¡ 7ȸÀÇ ºóµµ·Î ½É
ÇÑ ¾ß´¢ÁõÀ» º¸À̴ ȯÀÚ¿¡¼­ Ãʱ⿡ º¹Çվ๰¿ä¹ýÀ» ½ÃÇàÇÏ¿© ´ÙÀ½°ú °°Àº °á°ú¸¦ ¾ò¾ú´Ù.
1. Ãʱâ 2ÁÖ µ¿¾È¿¡ imipramine°ú desmopressinÀÇ º¹ÇÕ¿ä¹ý À» ½ÃÇàÇÑ °á°ú, ÁÖ°£ÀÇ ¹è´¢
Áõ»óÀ¯¹«¿Í °ü°è ¾øÀÌ Å« È¿°ú¸¦ º¼ ¼ö ÀÖ¾ú´Ù ±×·¯³ª, °¢°¢ÀÇ Åõ¾à³»¿ë¿¡ µû¸¥ °á°ú°¡ Åë
°èÀûÀ¸·Î´Â À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾úÀ¸¸ç, DE±º°ú ME±º »çÀÌ¿¡µµ ÀüüÀûÀÎ Ä¡·á¼ºÀû¿¡ ´ëÇؼ­
Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù.
2. Ãʱâ 2ÁÖ µ¿¾ÈÀÇ Ä¡·á¿¡¼­ ¼º°øÀûÀÎ ¹ÝÀÀÀ» º¸¿©ÁÖÁö ¾ÊÀº ȯ¾Æµé¿¡¼­ Åõ¾à³»¿ëÀ» ¹Ù²Û
´ÙÀ½ 4ÁÖ°£ Åõ¾àÀ» °è¼ÓÇÑ ´ÙÀ½¿¡ ÀçÆò°¡¸¦ ÇÏ¿´À» ¶§, desmopressinÀÇ ¿ë·®À» Áõ°¡½ÃÅ´À¸
·Î½á ¼º°ø·üÀ» Å©°Ô Çâ»ó½Ãų ¼ö ÀÖ¾ú´Ù.
3. Ãʱâ 2ÁÖ°£ÀÇ Ä¡·á¿¡ ¼º°øÀûÀÎ ¹ÝÀÀÀ» º¸¿© ÁÖ¾ú´ø ȯ¾ÆÀÇ ÀϺο¡¼­´Â imipramineÀÇ ¿ë
·®¸¸À» Àý¹Ý(12.5mg)À¸·Î ÁÙ¿©¼­ Åõ¾àÀ» °è¼ÓÇÏ¿´´Âµ¥ ÀÌ °¡¿îµ¥ 3¸í¿¡¼­´Â 4ÁÖ ÈÄ¿¡ ÀçÆò
°¡¸¦ ÇÏ¿´À» ¶§ Áõ»óÀÌ ¾ÇÈ­µÈ °ÍÀ» º¼ ¼ö ÀÖ´Ù.
4. Àüü 6ÁÖ°£ÀÇ Ä¡·á±â°£ µ¿¾È °æ¹ÌÇÑ ºÎÀÛ¿ëÀÌ ³ªÅ¸³­ °Í ÀÌ¿Ü¿¡´Â ¾à¹°¿¡ ÀÇÇÑ ºÎÀÛ¿ë
À¸·Î ÀÎÇÏ¿© Ä¡·á¸¦ Áß´ÜÇÒ Á¤µµÀÇ ½É°¢ÇÑ ºÎÀÛ¿ëÀº °üÂûµÇÁö ¾Ê¾Ò´Ù.
5. º¹Çվ๰¿ä¹ýÀÇ ÀüüÀûÀÎ Ä¡·á¼ºÀûÀº 76.5%À̾ú´Ù.
#ÃÊ·Ï#
Purpose: Recently there have been arguments about the exact nature of
pathophysiology of nocturnal enuresis. Desmopressin and imipramine have been used for
drug therapy. Also oxybutynin chloride has been used to treat the children having
nocturnal enuresis and diurnal voiding symptoms. Practically most nocturnal enuretic
patients who visit outpatient clinic really want to quit their enuretic episode quickly and
durably without side effect of drug therapy. We evaluated the effectiveness of combined
drug therapy in the primary nocturnal enuretic patients who had 7 times episodes in a
week.
Materials and Methods: In a total of 36 nocturnal enuretic patients(male:female=24:12)
whose ages ranged from 4- to 12-year-old(mean; 7.9-year-old), we initially used two or
three drugs among oxybutynin chloride(O) t.i.d., imipramine(I) h.s. and desmopressin(D)
h.5. for the 24 patients who have urgency and/or daytime enuresis(DE): O+l for 8
patients, O+D for 4,1+D for 4 and 0+1+D for 8. For 12 monosymptomatic enuretic(ME)
patients without having diurnal symptoms,0 h.s.+1 h.s.(in 5 patients) or 1 h.s.+D h.s.(in 7
patients) were used. Usual doses in a time are as follows: 2.5mg p.o. for 0,25mg p.o. for
1,20mg intranasally for D or 0.2mg p.o. for 8.
Results: At the first follow-up visit(2 weeks later), 14 patients had up to 3 enuretic
episodes in a 2 weeks period(judged as success) in the 24 DE patients. Among the
successful patients, 2 used O+l, 2 used O+D, 4 used 1+D and 6 used 0+1+D at the start.
In the 12 ME patients,5 had success. Four of the 5 successful patients had used 1+D.
At the second visit(6 weeks later from the beginning), 16 patients who had not showed
success at the first follow-up visit were analysed. Ten(6 DE and 4 ME) of the 16
patients became success. Five DE and 3 ME patients among the 10 successful patients
had newly used D or increased D dose during the second period. Three patients (1+D in
1 DE,0+1+D in 1 DE and 1+D in 1 ME)who had showed success at 2 week visit
became worse at 6-week visit after dose reduction in 1(12.5mg).
Conclusions: From the above data, we think that combined use of imipramine and
desmopressin is effective for initial treatment in the enuretic patients regardless of
diurnal symptom. To improve success rate, desmopressin dose needs to be increased.

Å°¿öµå

Enuresis; Combined drug therapy; imipramine; Desmopressin; Oxybutynin chloride;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS